• Waldenström Macroglobulinemia
  • Melanoma
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Childhood Cancers
  • Gastric Cancer
  • Gynecologic Cancer
  • Head & Neck Cancer
  • Immunotherapy
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma Cancer
  • Mesothelioma
  • MPN
  • MDS
  • Myeloma
  • Prostate Cancer
  • Rare Cancers
  • Sarcoma
  • Skin Cancer
  • Testicular Cancer
  • Thyroid Cancer

LCRF News: December 2022


Lung Cancer Research Foundation Announces 2022 Scientific Research Grant Awards: Foundation Awards $2.45 million in Research Grants to 15 Investigators

#TogetherSeparately Monthly Livestreams & Facebook Group

LCRF hosts webinars to bring the lung cancer community together to discuss topics important to them. Find out more and register for an upcoming livestream. The community also has a lively and engaged Facebook group.

View past #TogetherSeparately webinars here: https://www.lungcancerresearchfoundation.org/get-involved/togetherseparately-livestreams/

December’s #TogetherSeparately: Communicating with your Healthcare Team

Monday, December 12, 2022, 12:00pm - 1:00pm EST

Dr. Isabel Preeshagul will be joined by Dr. Cardinale B. Smith from the Tisch Cancer Center at Mount Sinai for our Lung Cancer Community Talk on Monday, December 12th at 12 PM ET. This livestream is an opportunity to connect face-to-face with others who care about lung cancer and talk about challenges we’re facing, #TogetherSeparately. We hope you'll join us for this important discussion on communicating with your healthcare team - including questions to ask your doctor, tips for improving communication with your care team, guidance for “my first visit”, advocating for your needs, and more. Registration opens November 10 at LCRF.org/Together

Newly Updated Educational Resources Available:

Updated Clinical Trials educational resource is now available at LCRF.org/clinicaltrials

Clinical trials are research studies that test new and promising treatments directly with patients. In fact, today’s gold standard treatment options were once studies in a clinical trial. These studies may also test new ways to prevent or diagnose diseases such as lung cancer. Clinical trials may include new ways to take medicine, radiation therapy, or surgery. Clinical trial teams make sure you receive the safest and best care. If you are recently diagnosed, you do not need to wait to consider a clinical trial for your treatment. No matter where you are in your treatment process, a clinical trial could be a good option for you.

LCRF updates its Comprehensive Biomarker Testing educational resource, now available for download:

You do not need to be a doctor to understand your tumor. Biomarker testing can help.

When your doctors suspected you had cancer, they took a small portion of your tumor tissue (a biopsy) to have it examined. A specialist, called a pathologist, looked at your tumor cells under the microscope and found out you had lung cancer. There are two main types of lung cancer–small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC). If you have NSCLC, the pathologist looks closely at the cancer cells for certain characteristics (features or qualities). Tumors with similar characteristics are referred to as subtypes. Adenocarcinoma (A-deh-noh-KAR-sih-NOH-muh) and squamous cell carcinoma (SKWAY-mus sel KAR-sih-NOH-muh) are the most common subtypes of NSCLC. Once your health care team knows the subtype of your cancer, treatment planning can begin. Read more & download your copy at LCRF.org/biomarkers.